Filing Flows › Companies › Emergent BioSolutions › Report card
Emergent BioSolutions earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate4 of 5 reports beat the EPS estimate
Emergent BioSolutions (EBS) beat the analysts' EPS estimate in 4 of its last 5 reports (80%), by +226.2% on average.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue guided | Revenue reported |
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 2, 2026 | −$0.39 | −$0.36 | +8.0% | — | $110M |
| Q2 2026 | Aug 5, 2026 | $0.11 | $0.60 | +445.5% | $170M–$185M | $234M (above) |
| Q1 2026 | Apr 30, 2026 | −$0.25 | $0.21 | +184.0% | — | $156M |
| Q4 2025 | Feb 26, 2026 | $0.11 | −$0.43 | -490.9% | — | $149M |
| Q3 2025 | Oct 29, 2025 | −$0.12 | $1.06 | +984.2% | — | $231M |
Estimates and reported EPS are the Street's adjusted figures. Revenue guided is the last range the company gave before the report. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Emergent BioSolutions: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.